Integra LifeSciences (NASDAQ: IART) reported Q1 EPS of $0.69, $0.12 better than the analyst estimate of $0.57. Revenue for the quarter came in at $360.1 million versus the consensus estimate of $349.81 million.

GUIDANCE:

Integra LifeSciences sees FY2021 EPS of $2.86-$2.93, versus the consensus of $2.90. Integra LifeSciences sees FY2021 revenue of $1.525-1.535 billion, versus the consensus of $1.53 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.